Khadega A. Abuelgasim

close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel In This Article Abstract and Introduction Abstract Background: Multiple myeloma has witnessed significant advances due to the approval of many novel agents. However, in spite of all these new developments, multiple myeloma remains an incurable disease with inevitable relapse in the majority of patients.

Abstract Background Multiple myeloma has witnessed significant advances due to the approval of many novel agents. However, in spite of all these new developments, multiple myeloma remains an incurable disease with inevitable relapse in the majority of patients. Venetoclax is a selective antiapoptotic protein B-cell lymphoma 2 inhibitor that induces cell death in multiple myeloma cells, particularly in those harboring t(11,14)(q13;q32).

There have been only 32 reported cases of CLL coexisting with CML in the same patient. The most commonly occurring pattern is for long-standing CLL to precede CML [4–9]. The patient in the present case report remained under careful observation for 3 years after being diagnosed as having CLL. Soon after completing fludarabine-based chemotherapy, he was diagnosed with CML. It is possible that this CML already existed before and was only detected after his CLL was brought under control.